[Special Stock] Gukjeon Yakpum Soars on News of Patent Application for COVID-19 Treatment
[Asia Economy Reporter Ji Yeon-jin] Raw material pharmaceutical company Gukjeon Pharm is soaring in the KOSDAQ market on the 9th.
As of 10:24 AM on the day, Gukjeon Pharm is trading at 9,240 KRW, up 25.34% from the previous day. The company announced that it has filed a patent application for the manufacturing of 'Nafamostat,' the main raw material of a COVID-19 treatment candidate substance.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Nana Home Intruder Who Filed 'Counter Attempted Murder Complaint' Referred to Prosecution for False Accusation
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The official name of the patent is "Method for Manufacturing Nafamostat Mesylate and Its Intermediates." Gukjeon Pharm improved the existing process to enhance the low binding strength, a physical property of Nafamostat. They also explained that they secured a manufacturing method to produce high-quality Nafamostat by synthesizing its intermediates using a differentiated manufacturing method.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
